Generic drugmaker Hindustan Laboratories files IPO papers to fund working capital

Hindustan Laboratories IPO News

• Hindustan Laboratories IPO | The company proposes to utilise Rs 72.5 crore from the fresh issue proceeds for working capital requirements.

Did our AI summary help?

Hindustan Laboratories, a Mumbai-based pharmaceutical company that manufactures generic medicines for government institutions under a business-to-government (B2G) framework, has filed draft documents with SEBI to raise funds through an initial public offering (IPO) of 1.41 crore shares.

The IPO comprises a fresh issue of 50 lakh shares and an offer for sale (OFS) of 91 lakh shares by Rajesh Vasantray Doshi, the company’s sole promoter.

The company proposes to utilise Rs 72.5 crore from the fresh issue proceeds for working capital requirements, with the remaining amount earmarked for general corporate purposes.

Incorporated in 2017, Hindustan Laboratories manufactures generic formulations—medicines for which patents have expired and which are typically used as substitutes for expensive branded drugs. The company primarily supplies products under procurement contracts for central government projects of the Ministry of Health and Family Welfare through Government of India (GoI) agencies, as well as to state government agencies and bodies.

Click Here To Read All IPO News

As of September 2025, its product portfolio comprised 948 products across therapeutic categories such as anti-allergic, anti-diabetic, anti-infective, anti-malarial, anti-parasitic, blood-related, cardiac, gastrointestinal, nutritional and mineral supplements, and pain and analgesics.

Hindustan Laboratories, which competes with listed peers such as Ajanta Pharma, Syncom Formulations, and Windlas Biotech, reported a profit of Rs 18.2 crore on revenue of Rs 112.6 crore for the six-month period ended September 2025.

For FY2025, the company recorded a profit of Rs 41.3 crore, reflecting a growth of nearly 21 percent from Rs 34.1 crore in the previous year. Revenue during the same period increased 17.9 percent to Rs 219.7 crore from Rs 186.4 crore.

Choice Capital Advisors has been appointed as the merchant banker for the Hindustan Laboratories IPO.